UPDATE ON DRUGS
|Class||Name/Company||Approval Dates and Comments|
|TPP Canada approved this biologic therapy in October 2005 for the|
treatment of moderate-to-severe chronic plaque psoriasis in adult
patients (18 years or older) who are candidates for systemic therapy
|The US FDA approved this biologic therapy in October 2005|
for reducing the signs and symptoms of active arthritis in
patients with psoriatic arthritis. This product can be used alone
or with methotrexate or other disease modifying antirheumatic
|The European Commission has granted approval of this|
biologic therapy in October 2005 for the treatment of moderateto-
severe plaque psoriasis in adults who failed to respond to, or
have a contraindication to, or are intolerant of other systemic
therapies including cyclosporine, methotrexate, or PUVA.
Diphtheria, Tetanus, Pertussis, Polio, Hemophilus Influenza
Type b Vaccine
Sanofi Pasteur MSD
|The US FDA accepted a Biologics Licensing Application|
in September 2005 for this pediatric combination vaccine
candidate that targets diphtheria, tetanus, pertussis, polio, and
Hemophilus influenzae type b.
Mupriocin Ointment 2%
|The US FDA approved an Abbreviated New Drug Application|
in September 2005 for this product for the treatment of
impetigo. It is bioequivalent to Bactroban® Ointment 2%
|The commercial launch of VANIQA® (eflornithine hydrochloride) cream 13.9% in Canada was|
announced by Barrier Therapeutics in November 2005. VANIQA® is the only topical prescription
product approved by Health Canada for slowing the growth of unwanted facial hair in women.
|In a July 2005 news release from the University of Texas Southwestern, dermatologists reported|
that when traditional methods to remove warts fail, such as burning, freezing, application
of salicylic acid and surgery, they inject Candida antigen directly into the wart. This antigen
stimulates the body’s own natural defense mechanism, and they report that it is as effective in
many instances as some of the more common therapies, but it doesn’t leave scarring.
|A hyaluronic acid dermal filler (Puragen®, Mentor Corporation) that is derived from bacterial|
fermentation using Mentor’s double cross-linked technology was launched in Europe in July
2005 for the treatment of wrinkles. Because it is a non-animal based product, it does not have the
risks associated with other products derived from animal by-products.